Glaukos/$GKOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Ticker
$GKOS
Sector
Primary listing
NYSE
Employees
995
Headquarters
Website
Glaukos Metrics
BasicAdvanced
$5B
-
-$1.65
0.82
-
Price and volume
Market cap
$5B
Beta
0.82
52-week high
$163.71
52-week low
$77.10
Average daily volume
1M
Financial strength
Current ratio
5.51
Quick ratio
4.521
Long term debt to equity
13.726
Total debt to equity
13.726
Interest coverage (TTM)
-17.43%
Profitability
EBITDA (TTM)
-62.5
Gross margin (TTM)
76.34%
Net profit margin (TTM)
-21.43%
Operating margin (TTM)
-22.33%
Effective tax rate (TTM)
-0.69%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-6.34%
Return on equity (TTM)
-12.98%
Valuation
Price to revenue (TTM)
11.344
Price to book
6.55
Price to tangible book (TTM)
11.71
Growth
Revenue change (TTM)
26.70%
Earnings per share change (TTM)
-48.43%
3-year revenue growth (CAGR)
14.51%
10-year revenue growth (CAGR)
22.13%
3-year earnings per share growth (CAGR)
11.68%
10-year earnings per share growth (CAGR)
-20.08%
What the Analysts think about Glaukos
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Bulls say / Bears say
Glaukos' iStent portfolio has significantly boosted its glaucoma franchise revenues, with the launch of iDose TR in Q2 2024 further enhancing revenue growth. (nasdaq.com)
The company is expanding its international presence, with its international glaucoma franchise recording 17% growth from the comparable period in 2023. (nasdaq.com)
Analysts predict strong adoption of Glaukos' iDose, with a Citigroup survey revealing that 70% of ophthalmologists plan to adopt iDose once available. (wallstreetzen.com)
The FDA denied approval to Glaukos' pre-market approval application for the MicroShunt device, leading to uncertainties about its U.S. commercial launch. (nasdaq.com)
Glaukos faces stiff competition from other medical companies and institutions developing new treatments for glaucoma, which could render its products obsolete. (nasdaq.com)
The company relies on a limited number of third-party suppliers for components of its products; any disruption in supply could adversely affect production. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Glaukos Financial Performance
Revenues and expenses
Glaukos Earnings Performance
Company profitability
Glaukos News
AllArticlesVideos
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
Business Wire·4 weeks ago
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
Business Wire·1 month ago
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Glaukos stock?
Glaukos (GKOS) has a market cap of $5B as of August 05, 2025.
What is the P/E ratio for Glaukos stock?
The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of August 05, 2025.
Does Glaukos stock pay dividends?
No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of August 05, 2025.
When is the next Glaukos dividend payment date?
Glaukos (GKOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Glaukos?
Glaukos (GKOS) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.